脓毒症患者连续性血液滤过治疗对首剂利奈唑胺血药浓度的监测分析

发布时间：2018-05-01 03:40

本文选题：连续性静-静脉血液滤过 + 脓毒症　；参考：《中华医院感染学杂志》2015年06期

【摘要】：目的调查肾替代治疗中的连续性静-静脉血液滤过(CVVH)对脓毒症患者首剂利奈唑胺血药浓度的影响。方法调查2011年7月-2012年1月严重脓毒症使用利奈唑胺治疗的18例患者临床资料,根据随机原则分为CVVH组8例、非CVVH组10例,两组均给予首剂利奈唑胺600mg,给药时间为1h;CVVH治疗采用统一规格滤器滤过,血流速度设定为150ml/h,置换液速度设定为2 000ml/h;于给药后0、30min、1、2、3、5、7、9、11h时测定外周血利奈唑胺血药浓度及滤过前后静脉血利奈唑胺血药浓度,同时监测CVVH治疗超滤后废液中利奈唑胺的血药浓度。结果两组患者外周静脉血利奈唑胺血药浓度比较差异无统计学意义,CVVH组平均血药浓度3.35~6.23mg/L,非CVVH组为4.34~9.81mg/L;CVVH组滤器前后各时点利奈唑胺的血药浓度的比较差异无统计学意义,滤过前平均血药浓度在4.03~5.93mg/L,滤过后平均血药浓度在3.89~5.76mg/L;CVVH治疗超滤后废液中利奈唑胺剂量为26.80~316.96 mg。结论 CVVH治疗会降低利奈唑胺血药浓度,但无需调整治疗剂量。
[Abstract]:Objective to investigate the effect of continuous veno-venous hemofiltration (CVVH) in renal replacement therapy on the serum concentration of the first dose of linazolamide in patients with sepsis. Methods from July 2011 to January 2012, 18 patients with severe sepsis treated with linazolamide were randomly divided into CVVH group (n = 8) and non- group (n = 10). Both groups were given the first dose of linazolamide 600 mg and the time of administration was 1 h for CVVH treatment with uniform filter filter. The blood flow velocity was set at 150 ml / h and the replacement fluid was set at 2 000 ml / h. The blood concentration of lenizolamine in peripheral blood and the concentration of lenizolamine in venous blood before and after filtration were determined at 30 min after administration of CVVH. Results there was no significant difference between the two groups in the blood concentration of lenazolidomide in peripheral vein blood. The average plasma drug concentration in the CVVH group was 3.35 卤6.23 mg / L, and that in the non-CVVH group was 4.34 ~ 9.81 mg / L before and after the filter. There was no significant difference in the blood drug concentration between the two groups before and after the filter, and there was no significant difference between the two groups before and after the filter. The mean blood drug concentration before filtration was 4.03 ~ 5.93 mg / L, and that after filtration was 3.89 ~ 5.76 mg 路L ~ (-1) 路L ~ (-1). The dosage of lenazolamine in ultrafiltration waste solution was 26.80 ~ 316.96 mg 路L ~ (-1) 路L ~ (-1) 路L ~ (-1) 路L ~ (-1) ~ (-1) ~ (-1) ~ (-1). Conclusion CVVH treatment can reduce the serum concentration of linazolamide, but do not need to adjust the dosage of the treatment.
【作者单位】：中国医科大学附属盛京医院重症医学科;
【基金】：辽宁省自然科学基金资助项目(201102293)
【分类号】：R978.1

【相似文献】